Mali Trial Finds Malaria Antibody Protects Infants but Blunts R21 Vaccine Response

American Society of Tropical Medicine & Hygiene

A single intramuscular dose of an experimental malaria monoclonal antibody safely provided infants with strong protection during Mali's six-month malaria season; however, potential interference with the R21 malaria vaccine is pausing plans to pursue development of L9LS for this age group, according to results from a clinical trial presented at the Annual Meeting of the American Society of Tropical Medicine and Hygiene (ASTMH).

The Phase 1b trial involved a monoclonal antibody known as L9LS that was developed by the U.S. National Institute of Allergy and Infectious Diseases (NIAID). The antibody has a strong track record of safety and efficacy in clinical trials involving older children in Mali and Kenya.

"We wanted to test L9LS in infants as young as 1 month old, because children are not eligible for malaria vaccination until they are at least 5 months old — and that leaves them especially vulnerable, particularly during times of intense malaria transmission," said Kassoum Kayentao, a physician-scientist at the University of Sciences, Techniques and Technologies in Bamako, Mali, which conducted the trial in partnership with NIAID colleagues. "While protective efficacy against malaria infection was 78%, the monoclonal antibody also appeared to interfere with the immune response to subsequent immunization with the R21 malaria vaccine, which is widely used in Mali. That means we must pause our plans to conduct a larger trial with infants."

Researchers said they will continue exploring the potential of L9LS to reduce the burden of malaria in children who remain at risk of malaria after completing the R21 vaccine series, since the vaccine does not provide complete and long-lasting protection. For example, L9LS may potentially be used for post-discharge prophylaxis in hospitalized children with severe malaria or anemia, or as a potential alternative to seasonal malaria chemoprevention following vaccination. Dr. Kayentao said there is also interest in considering L9LS for pregnant women given the significant morbidity and mortality associated with malaria during pregnancy.

Despite setback with infants, L9LS continues to show strong protective efficacy

Malaria monoclonal antibodies, or "mAbs," are naturally occurring proteins isolated from human immune cells in the laboratory and then manufactured in large quantities. These mAbs are intended to provide nearly immediate protection that lasts for about six months. There is considerable interest in deploying them in the fight against malaria. According to the World Health Organization, about 610,000 people died from malaria in 2024, most of them young African children. That toll that has barely budged in the last 10 years, possibly due in part to a rise in anti-malarial drug and insecticide resistance.

L9LS is the most advanced malaria mAb in the pipeline. In previous trials involving infants and older children in Mali and Kenya , a single subcutaneous injection of L9LS — meaning it was injected into tissue just beneath the skin — proved highly efficacious in preventing malaria illness.

The results from the latest Mali trial were presented at the ASTMH Annual Meeting by lead author Bickey Chang, M.D., a clinical fellow at NIAID. The trial, which was conducted in 2024 and 2025 at three sites in Mali, enrolled 180 healthy children ages 1-12 months. Half received L9LS, which was delivered via an intramuscular injection. (Compared to a subcutaneous injection, this route of administration can speed absorption of a medication by injecting it deep into muscle tissue.) The other half received a placebo injection of sterile salt water. L9LS was safe and well tolerated by those who received it and provided protective efficacy of 78% against infection with the Plasmodium falciparum malaria parasite, the deadliest of the Plasmodium species that infect humans and the most prevalent one in Africa.

But the researchers also observed that a key antibody response generated by the R21 vaccine was about 20% to 30% lower in study participants who received L9LS 5 months before receiving the vaccine, compared to those who had received placebo. This mAb-vaccine interaction may be due to the fact that L9LS binds weakly to the malaria protein contained in the R21 vaccine, even though that protein is not the primary target of L9LS. Further clinical development of L9LS for children who have not completed the three-dose R21 vaccine series—those less than 2 to 3 years of age--will not be considered until researchers can determine whether the observed reduction in antibody production actually compromises protection provided by the R21 vaccine. The researchers also noted that there are other malaria mAbs now in early stages of development that are less likely to interfere with R21.

"The L9LS monoclonal antibody is one of the most exciting malaria interventions now in development, and that makes it all the more important to evaluate interactions with other tools now in use," said ASTMH President Terrie Taylor, a malaria researcher with extensive field experience in Malawi. "The potential interference with R21 is a crucial outcome to consider, though, because of its demonstrated efficacy. Overall, the study is a reminder that blazing a trail for a scientific breakthrough rarely involves a straight pathway to success. It highlights why we should value scientists who are committed to thoroughly exploring innovations targeting malaria mortality from one end of the lifespan to the other."

The content of this press release is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

/Public Release. This material from the originating organization/author(s) might be of the point-in-time nature, and edited for clarity, style and length. Mirage.News does not take institutional positions or sides, and all views, positions, and conclusions expressed herein are solely those of the author(s).View in full here.